Get the Stockscreener App
31.34
9.55%
-3.31
Monopar Therapeutics Inc stock is traded at $31.34, with a volume of 30,458.
It is down -9.55% in the last 24 hours and down -15.00% over the past month.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
See More
Previous Close:
$34.65
Open:
$35.8
24h Volume:
30,458
Relative Volume:
0.83
Market Cap:
$191.65M
Revenue:
-
Net Income/Loss:
$-7.12M
P/E Ratio:
-13.63
EPS:
-2.3
Net Cash Flow:
$-6.82M
1W Performance:
-24.93%
1M Performance:
-15.00%
6M Performance:
-38.94%
1Y Performance:
+6,990%
1-Day Range:
$30.51
$35.80
1-Week Range:
$30.51
$42.50
52-Week Range:
$0.3438
$54.30
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Name
Monopar Therapeutics Inc
Sector
Industry
Phone
(847) 388-0349
Address
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
31.34 | 211.89M | 0 | -7.12M | -6.82M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
374.46 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
435.00 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.94 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
638.90 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
289.75 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-23-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-19-25 | Resumed | Piper Sandler | Overweight |
| Jan-10-25 | Initiated | Piper Sandler | Overweight |
| Oct-11-24 | Initiated | Rodman & Renshaw | Buy |
| Jan-28-21 | Initiated | ROTH Capital | Buy |
View All
Monopar Therapeutics Inc Stock (MNPR) Latest News
Will Monopar Therapeutics Inc. stock go up soonAI Pattern Recognition and Trade Prediction - Newser
Monopar Therapeutics Inc. stock trendline breakdownRisk Managed Watchlist with Breakout Picks - Newser
Does Monopar Therapeutics Inc. fit your quant trading modelRisk/Reward Optimization Entry Point Analysis - Newser
Applying Elliott Wave Theory to Monopar Therapeutics Inc.Watchlist Summary for Active Day Traders - Newser
Chart based exit strategy for Monopar Therapeutics Inc.Free Strong Buy With Technical Confidence - Newser
Is it too late to sell Monopar Therapeutics Inc.Investment Roadmap for High Potential Stocks - Newser
How Monopar Therapeutics Inc. stock performs during market volatilityStock Price Prediction Using AI Tools - Newser
Monopar Therapeutics Inc. stock volume spike explainedSwing Trade Timing with Daily Forecast - Newser
What makes Monopar Therapeutics Inc. stock price move sharplyWeekly Chart-Based Forecast for Traders - Newser
How to monitor Monopar Therapeutics Inc. with trend dashboardsStock Holding Strategy Long-Term Summary Sheet - Newser
Does Monopar Therapeutics Inc. qualify in momentum factor screeningShort-Term Stock Trend Forecast Guide - Newser
When is the best time to buy Monopar Therapeutics Inc. stockFree Weekly Hot Picks With Buy Confidence - Newser
Can swing trading help recover from Monopar Therapeutics Inc. lossesSmart Entry Watchlist with Daily Analysis - Newser
What momentum shifts mean for FWONAPattern Breakout Prediction for Short Term - Newser
How to use a screener to detect Monopar Therapeutics Inc. breakoutsHigh Confidence Strategy with Trend Alignment - Newser
Is Monopar Therapeutics Inc. showing signs of accumulationShort Term Momentum Based Trading Strategy - Newser
Why Monopar Therapeutics Inc. stock attracts strong analyst attentionFree Fundamental + Technical Hybrid Stock Tips - Newser
Monopar Therapeutics MNPR Q2 2025 Earnings Preview Downside Risk Amid Increased Operating Expenses - AInvest
Monopar Therapeutics Inc expected to post a loss of 47 cents a shareEarnings Preview - TradingView
Forecasting Monopar Therapeutics Inc. price range with options dataPredictable Entry Strategy With Technical Backing - Newser
Is Monopar Therapeutics Inc. a good long term investmentDiscover undervalued stocks before they soar - Jammu Links News
How strong is Monopar Therapeutics Inc. company’s balance sheetBuild a diversified portfolio for steady profits - Jammu Links News
What drives Monopar Therapeutics Inc. stock priceAchieve rapid portfolio appreciation today - Jammu Links News
Is Monopar Therapeutics Inc. a growth stock or a value stockBuild wealth steadily with smart stock selection - Jammu Links News
When is Monopar Therapeutics Inc. stock expected to show significant growthInvest smarter with data-backed trading alerts - Jammu Links News
What are the latest earnings results for Monopar Therapeutics Inc.Capitalize on fast-moving stock opportunities - Jammu Links News
What are the technical indicators suggesting about Monopar Therapeutics Inc.Capitalize on market momentum for profits - Jammu Links News
Monopar Therapeutics Inc. stock trend outlook and recovery pathFundamental + Technical Combined Watchlist - Newser
What are analysts’ price targets for Monopar Therapeutics Inc. in the next 12 monthsIdentify undervalued stocks ready to soar - Jammu Links News
How many analysts rate Monopar Therapeutics Inc. as a “Buy”Free Trend-Following Techniques - Jammu Links News
Will Monopar Therapeutics Inc. price bounce be sustainableFree Fundamental Growth Stock Analysis - Newser
Combining price and volume data for Monopar Therapeutics Inc.Investment Timing Strategy with Market Filters - newser.com
Is it the right time to buy Monopar Therapeutics Inc. stockExponential return rates - Jammu Links News
How volatile is Monopar Therapeutics Inc. stock compared to the marketHigh-yield market plays - Jammu Links News
What is the dividend policy of Monopar Therapeutics Inc. stockBuild a diversified portfolio for steady profits - Jammu Links News
Monopar Therapeutics Inc Stock (MNPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.02%
3.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):